How have CNSP shares performed in 2024?

CNS Pharmaceuticals' stock was trading at $1.27 at the beginning of 2024. Since then, CNSP stock has decreased by 83.9% and is now trading at $0.2045. View the best growth stocks for 2024 here .

Are investors shorting CNS Pharmaceuticals?

CNS Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 50,000 shares, a decrease of 51.8% from the March 15th total of 103,800 shares. Based on an average trading volume of 417,100 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.5% of the company's shares are short sold. View CNS Pharmaceuticals' Short Interest .

When is CNS Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CNSP earnings forecast .

How were CNS Pharmaceuticals' earnings last quarter?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.73) by $0.65.

When did CNS Pharmaceuticals' stock split?

CNS Pharmaceuticals shares reverse split before market open on Tuesday, November 29th 2022. The 1-30 reverse split was announced on Tuesday, November 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC) , Advanced Micro Devices (AMD) , Heat Biologics (HTBX) , Roku (ROKU) , Aldeyra Therapeutics (ALDX) , Salesforce (CRM) , Gilead Sciences (GILD) , Inseego (INSG) , Nokia Oyj (NOK) and Block (SQ) .

When did CNS Pharmaceuticals IPO?

CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO.

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CNSP

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free CNSP Stock Alerts

$0.21

+0.01 (+2.74%)

(As of 09:03 AM ET)

Compare

Today's Range: $0.21
▼
$0.21
50-Day Range: $0.20
▼
$0.45
52-Week Range: $0.19
▼
$3.35

Volume: 1,708 shs
Average Volume: 378,807 shs
Market Capitalization: $2.23 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get CNS Pharmaceuticals alerts:

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNSP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CNSP Stock News Headlines

April 16, 2024 | americanbankingnews.com

Analyzing Arcutis Biotherapeutics (NASDAQ:ARQT) and CNS Pharmaceuticals (NASDAQ:CNSP)

April 4, 2024 | theglobeandmail.com

CNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 3, 2024 | benzinga.com

CNS Pharma Stock (NASDAQ:CNSP), Earnings Estimates, EPS, and Revenue

April 2, 2024 | investorplace.com

CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023

March 20, 2024 | theglobeandmail.com

CNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Board

February 9, 2024 | investing.com

Cns Pharmaceuticals Inc (CNSP)

February 3, 2024 | msn.com

CNS Pharmaceuticals Launches Public Offering for Trial Funding

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

January 30, 2024 | theglobeandmail.com

CNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering Pricing

January 29, 2024 | finanznachrichten.de

CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

January 29, 2024 | finance.yahoo.com

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

January 19, 2024 | theglobeandmail.com

CNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors

January 18, 2024 | finanznachrichten.de

CNS Pharmaceuticals, Inc.: Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

January 18, 2024 | finance.yahoo.com

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

January 17, 2024 | finance.yahoo.com

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

January 6, 2024 | seekingalpha.com

CNSP CNS Pharmaceuticals, Inc.

December 18, 2023 | finance.yahoo.com

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

December 14, 2023 | morningstar.com

CNS Pharmaceuticals Inc Ordinary Shares

December 8, 2023 | msn.com

CNS Pharmaceuticals files to sell 3.81M shares of common stock

December 6, 2023 | finance.yahoo.com

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

November 22, 2023 | finance.yahoo.com

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

November 21, 2023 | msn.com

CNS Pharmaceuticals files to sell 3.76M shares of common stock for holders

November 16, 2023 | finance.yahoo.com

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

November 15, 2023 | finance.yahoo.com

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

November 11, 2023 | morningstar.com

CNS Pharmaceuticals Inc Ordinary Shares CNSP

October 19, 2023 | finance.yahoo.com

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

See More Headlines

Receive CNSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 4/17/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CNSP
CUSIP: N/A
CIK: 1729427
Web: www.cnspharma.com
Phone: 800-946-9185
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($5.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,850,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -603.40%
Return on Assets: -421.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.26
Quick Ratio: 0.26

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.71) per share
Price / Book: -0.29

Miscellaneous

Outstanding Shares: 10,640,000
Free Float: 10,222,000
Market Cap: $2.18 million
Optionable: Not Optionable
Beta: 2.67

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. John Michael Climaco Esq. (Age 55)
J.D., CEO, President & Director
Comp: $525k
Mr. Christopher S. Downs CPA (Age 46)
CTP, FP&A, Chief Financial Officer
Comp: $340k
Dr. Sandra L. Silberman M.D. (Age 69)
Ph.D., Chief Medical Officer
Comp: $200k
Dr. Waldemar Priebe Ph.D.
Founder
Dr. Donald H. Picker Ph.D. (Age 78)
Chief Science Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CNSP Stock Analysis - Frequently Asked Questions

How have CNSP shares performed in 2024?: CNS Pharmaceuticals' stock was trading at $1.27 at the beginning of 2024. Since then, CNSP stock has decreased by 83.9% and is now trading at $0.2045.
View the best growth stocks for 2024 here.
Are investors shorting CNS Pharmaceuticals?: CNS Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 50,000 shares, a decrease of 51.8% from the March 15th total of 103,800 shares. Based on an average trading volume of 417,100 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.5% of the company's shares are short sold.
View CNS Pharmaceuticals' Short Interest.
When is CNS Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CNSP earnings forecast.
How were CNS Pharmaceuticals' earnings last quarter?: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.73) by $0.65.

When did CNS Pharmaceuticals' stock split?: CNS Pharmaceuticals shares reverse split before market open on Tuesday, November 29th 2022. The 1-30 reverse split was announced on Tuesday, November 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of CNS Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), Salesforce (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia Oyj (NOK) and Block (SQ).
When did CNS Pharmaceuticals IPO?: CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO.
How do I buy shares of CNS Pharmaceuticals?: Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNSP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

CNSP Stock Price History

CNSP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CNSP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info